QUOTE AND NEWS
Benzinga  Jul 20  Comment 
In a report published Monday, Piper Jaffray analyst Matt O'Brien initiated coverage of Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) with an Overweight rating and price target of $35. The analyst believes that the company sells the "best body contouring...
Benzinga  Jun 19  Comment 
The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday June 18, 2015: Lumenis to be Acquired for $14.00/Share, In Cash The Deal: Lumenis Ltd. (LMNS) announced Thursday that it has agreed to be acquired by XIO...
Benzinga  Jun 3  Comment 
In a report published Tuesday, Goldman Sachs analyst David Roman revisited the small-cap names under his coverage and noted that he is sticking with his view that product cycles and U.S. cyclical exposure (hospital capex/utilization) remain the...
Benzinga  Jun 3  Comment 
Goldman Sachs upgraded Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) from Neutral to Buy. Zeltiq Aesthetics shares have gained 74.13 percent over the past 52 weeks, while the S&P 500 index has surged 9.43 percent in the same period. Zeltiq Aesthetics'...
Benzinga  May 14  Comment 
ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it recently shipped its 2,000,000th...
Motley Fool  May 5  Comment 
The company behind the CoolScuplting fat cell freezing platform delivers another quarter of growth.
DailyFinance  Feb 13  Comment 
Filed under: Company News, Market News, Investing PeJo/Shutterstock If January is about making New Year's resolutions, February has to be about breaking them -- or cutting corners to make things happen. Along comes Zeltiq Aesthetics (ZLTQ) --...




 
TOP CONTRIBUTORS

ZELTIQ Aesthetics (NASDAQ:ZLTQ) is a medical device company which developed and sells a fat reduction device called CoolSculpting. The system selectively cools regions of fat to increase their rate of elimination by the body. The procedure is targeted for individuals with relatively small fat bulges rather than for obese individuals. This is because the technology is typically ineffective on obese individuals who require significant decreases in their body fat. Zeltiq makes money by selling the systems to physicians as well as charging procedure fees for each treatment performed.[1]

Business Overview

Zeltiq's total revenue for the full year 2010 was $25.5M. This compares to a total revenue of $1.6M in 2009. However, the company reported a net loss of 2010 of $13.5M. This is an improvement over the net loss of $17.6M in 2009. While Zeltiq has historically had a large research and development expense, this costs was surpassed by sales and marketing in 2010. [2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on October 18, 2011. The company offered 7M shares each for $13. This was below the $14-$16 price range. The company raised $91M through the deal. The lead managers of the deal were JP Morgan and Goldman.[3]

Trends & Forces

Reliance on luxury health

Because Zeltiq's devices aim to help individuals with relatively small fat bulges, the demand for their product is largely an additional luxury good. Unlike procedures aimed at obese individuals, the use of CoolSculpting does not prevent or solve an immediate health risk. As a result, demand for such a service will rest on individuals who are willing and able to pay for cosmetic improvements. By contrast, since the procedure is noninvasive and treats fat bulges, the potential demand for the product is likely quite large. [4][5]

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki